Faculty

Sebastien Lustig, MD, PhD, Prof.

Lyon North University Hospital
Lyon, Rhône Alpes FRANCE

Sébastien Lustig is a hip and knee reconstructive surgeon and Professor of Orthopaedics Surgery at Lyon North University Hospitals in Lyon, France. He is Chair of the Orthopaedic Department, Director of the Orthopaedic program at Lyon University and board member of the European Knee Society and of the French hip and Knee Society. He is also Deputy Editor of The Journal of Bone & Joint Surgery American.
http://www.orthopedie-lyon-croix-rousse.fr

Thu 10/31
07:45 - 08:00
Mizuho-no-ma North Welcome to Day One: Primary Total Knee Replacement and Partial Knee Replacement
Introduction
Introduction
Director
Thu 10/31
08:00 - 09:30
Mizuho-no-ma North Session 1: Alignment

Moderator
Thu 10/31
09:25 - 09:30
Mizuho-no-ma North Session 1: Alignment
Presentation
Final Summary with Critical Take Home Messages
Moderator
Thu 10/31
16:35 - 16:43
Mizuho-no-ma North Session 6: Robotic Technology
Presentation
How to Evaluate and Choose the Best Robot for You
Faculty
Fri 11/01
08:15 - 08:30
Mizuho-no-ma North Welcome to Day Two: Partial Knee, Complex Primary and Revision

Director
Fri 11/01
08:15 - 08:30
Mizuho-no-ma North Welcome to Day Two: Partial Knee, Complex Primary and Revision
Introduction
Introduction
Director
Fri 11/01
08:46 - 08:54
Mizuho-no-ma North Session 7: Patellofemoral Arthroplasty
Presentation
Indications and Contraindications for Isolated Patellofemoral Arthroplasty
Faculty
Fri 11/01
14:00 - 15:00
Mizuho-no-ma North Session 9: Revision Case-based Presentations: Infection
Global Case-based Discussion Session
Revision Case-based Presentations: Infection
Faculty
Fri 11/01
15:00 - 16:00
Mizuho-no-ma North Session 10: Revision Case-Based Presentations: Instability

Moderator
Fri 11/01
15:00 - 16:00
Mizuho-no-ma North Session 10: Revision Case-Based Presentations: Instability
Global Case-based Discussion Session
Revision Case-Based Presentations: Instability
Moderator

Disclosures

No Financial Conflicts to Disclose
All relevant financial disclosures have been mitigated.